CPPs (cell-penetrating peptides) can be defined as short peptides that are able to efficiently penetrate cellular lipid bilayers. Because of this remarkable feature, they are excellent candidates regarding alterations in gene expression. CPPs have been utilized in in vivo and in vitro experiments as delivery vectors for different bioactive cargoes. This review focuses on the experiments performed in recent years where CPPs have been used as vectors for multiple effectors of gene expression such as oligonucleotides for antisense, siRNA (small interfering RNA) and decoy dsDNA (double-stranded DNA) applications, and as transfection agents for plasmid delivery.
Introduction
Since their first description in the literature in 1994 [1] , CPPs (cell-penetrating peptides) have been employed as delivery vectors for a vast variety of cargoes, varying from gold particles to entire plasmids. Although many years have passed, there is still no unambiguous description of what a CPP really is. In a wide sense, CPPs can be described as peptides that have the ability to translocate to the plasma and/or nuclear membrane either alone or together with a desired cargo. Apart from this common feature, CPPs are a straggling family of peptides ranging from short highly cationic peptides such as polyarginine [2] to longer more amphipathic peptides such as transportan [3] . The most studied peptides, Tat (transactivator of transcription) [4] and penetratin [1] , are both derived from naturally occurring shuttling proteins, whereas other CPPs are either chimaeric or totally synthetic peptide sequences. As a whole, CPPs are promising vectors for a wide range of therapeutics. However, there are still many impediments to overcome before they can be utilized in clinical trials. Special interest is to improve the delivery of oligonucleotides, with a further aim of gene therapy; this mini-review summarizes the recent progress in this field.
Uptake mechanisms for CPPs
In recent years, much effort has been put into elucidating the mechanism of CPP internalization. In this respect, CPPs are hard to define. Recent data suggest that endocytosis contributes to the uptake, and caveolae, clathrin-dependent endocytosis and macropinocytosis have been suggested to mediate CPP translocation [5] [6] [7] . To make things even more complicated, there are reports claiming that uptake is independent of endocytotic pathways and occurs through transient pore formation [8, 9] .
CPPs, when not attached to cargo, seem to use different pathways to translocate into the intracellular environment. Endocytotic, as well as non-endocytotic, uptake of CPPs, i.e. 'naked' peptides, have been demonstrated. However, for cargo-conjugated CPPs, the endocytotic translocation pathway seems to prevail, according to recent experiments [11, 30] . Additionally, by comparison of uptake of different CPPs, it has been suggested that these peptides simultaneously utilize different submechanisms of endocytosis and, at higher concentrations, uptake occurs by an additional rapid translocation process [10] .
Several endocytotic pathways seem to be involved in the uptake of the CPP-oligonucleotide conjugates, depending on the specific CPP, oligonucleotide cargo and, probably, on the bioactivity assay method used.
Recently, the designed endosomolytic peptide EB1 (endosomal breaker 1) was introduced and applied to the biologically active siRNA (small interfering RNA) (luciferase silencing) delivery by non-covalent coupling of EB1 peptide and siRNA [12] . Various well-known CPPs were compared in this study for their ability to induce siRNA-mediated gene silencing; however, the best results were achieved with the EB1 peptide. This peptide was expected to protonate in early endosomes owing to the lower pH and extra histidine residues in the sequence resulting in permeabilization of the endosomal membrane. Novel CPPs with improved endosomolytical properties are suggested for in vivo applications in the future. It is also of importance that the differential membrane perturbation is caused by the CPPs attached to different cargoes, and this should be considered in future design of better delivery vectors of oligonucleotides [13] .
CPPs for plasmid delivery
Very few studies on CPP delivery of entire plasmids have been reported. However, Liu et al. [14] showed in 2005 that, although Tat alone has no significant transfection capability, a branched Tat structure was able to complex with plasmid DNA and displayed significant transfection capabilities in a variety of mammalian cell lines through an endocytosismediated pathway. In line with these results, TP10 (transportan 10) is not capable of promoting plasmid uptake either when co-incubated with or conjugated to a plasmid via a PNA (peptide nucleic acid) linker. However, TP10 conjugation with PEI (polyethyleneimine) or addition of TP10 to standard PEI transfection increases transfection efficacy severalfold. Increase is most significant at low PEI concentrations, enabling reduced PEI concentration without loss of gene delivery. Both protocols of enhanced PEI transfection were shown to be dependent upon endocytosis [15] .
Another delivery strategy enhanced by CPPs is MEND (multifunctional envelope-type nano device) which mimics an envelope-type virus. MEND particles containing DNA packaged into a lipid envelope modified with an octa-arginine peptide achieve transfection comparable with adenovirusmediated transfection. Topical application of MEND particles containing constitutively active BMP (bone morphogenetic protein) type IA receptor (caBmpr1a) gene had a significant impact on hair growth in vivo. The strategy mediates internalization via macropinocytosis, thereby avoiding lysosomal degradation [16] .
siRNA as cargo for CPPs
The inability of naked siRNA to translocate into the intracellular environment has initiated, among other transfection methods, the applications of CPPs in siRNA delivery. Only a few reports are available today concerning this subject (Table 1) , and the reported effects of siRNA are modest, falling into the range of 50-60% of gene silencing. Difficulties for successful applications of CPPs in siRNA delivery are many, from the disturbing electrostatic interactions between positively charged CPPs and negatively charged siRNA, to inefficient endosomal escape of the conjugates. In the reports available, gene silencing by CPP-conjugated siRNA utilizes, in three cases, a luciferase reporter gene as a convenient system for a relatively simple readout [12, 38, 42] . The peptides MPGα [derived from the fusion sequence of HIV-1 gp41 (glycoprotein 41) together with the nuclear localization sequence of SV40 (simian virus 40)], EB1 and bPrP (bovine prion protein peptide) have shown 50-60% down-regulation of luciferase expression in these studies (see Table 1 ). R 8 -modified liposomes and R 8 -modified MEND systems give promise to use CPPs in more complex lipoplex systems in future. Inhibition of proliferation in cancer cells could lead to promising novel strategies in cancer treatment, and this has been achieved recently in a few cases.
Hence, the real breakthrough would be to apply the relatively mild CPP-delivery technology to siRNA silencing of genes, and hopefully such innovation is on its way, as indicated by Meade and Dowdy [17] .
CPPs as delivery vectors for asONs (antisense oligonucleotides)
Modulating protein expression levels using asONs holds great promise not only in basic research to elucidate protein function, but also in clinical settings to down-regulate the expression of overexpressed proteins. Also, asONs have been utilized to redirect splicing and correct pre-mRNAs by blocking aberrant splice sites, with concomitant sterical blocking of spliceosome binding, or to shift splicing towards specific protein isoforms [18] . Although targeting mRNAs for degradation or controlling pre-mRNA splicing patterns with asONs constitutes an attractive way to potentially treat and manage a variety of diseases, the low bioavailability of these compounds restricts their potential use. Several lipidbased vectors have been developed to confer internalization of various oligonucleotide analogues, but their applications are restricted by potential cytotoxicity and inability to transport uncharged compounds such as PNAs inside cells. Therefore CPPs have been coupled to asONs on a regular basis, showing great potential to increase the bioavailability significantly. We will cover here the recent advances made in the field of CPPs regarding the delivery of asONs using different conjugation strategies (see Table 1 ).
Gait and co-workers have shown nicely that, by conjugating transportan or R 6 -penetratin via a disulfide bridge to a 16-mer PNA targeting the TAR (transactivation response) region of an HIV RNA transcript, HIV-1 Tat-dependent transactivation in a HeLa cell assay can be blocked, emphasizing the potential of developing new antiviral agents [19] . Similar results on antiviral activity with PNA targeting HIV-1 replication were also obtained by another group utilizing the widely used CPPs Tat and penetratin conjugated to two different PNAs, again via a disulfide bridge [20] . Although the vast majority of studies of CPP-mediated asON delivery have been performed using covalent conjugates, others have employed a co-incubation strategy where peptides are simply mixed with oligonucleotides, allowing them to form noncovalent complexes. This was first successfully exploited by the group of Divita, who showed that by mixing an amphipathic CPP, Pep-2, with PNA or HypNA-pPNA (hydroxyprolyl-phosphono-PNA) targeting cyclin B1, a significant reduction in cyclin expression was observed with concomitant cell cycle arrest [21] . Interestingly, the modified PNA displayed superior antisense activity as compared with ordinary PNA. Very recently, the same group presented a shorter Pep peptide named Pep-3, which forms stable nano-size complexes with the abovementioned PNAs [22] . Interestingly, the peptide appears to be more potent than existing transfection reagents in conferring uptake of its cargo [36] in different cell lines [22] . More importantly, the authors show that Pep-3-HypNA-pPNA complexes administered in vivo reduce tumour growth by targeting the cyclin B1 mRNA [22] . As mentioned previously, asONs have also been used to modulate splicing patterns of various pre-mRNAs, reviewed in [23] . Most studies on splice correction have utilized different cationic lipids or oligolysine as vectors for splicecorrecting oligonucleotides. However, cationic lipid formulas are incompatible with uncharged oligonucleotides, and oligolysines have limited transport capabilities, as shown recently [24] . In the search for new efficient delivery vectors, Kang et al. [25] constructed a splicing reporter system. Briefly, a plasmid carrying the luciferase-coding sequence is interrupted by an insertion of intron 2 from β-globin pre-mRNA carrying a cryptic splice site. Unless the aberrant splice site is masked by antisense oligonucleotides, the premRNA of luciferase will be improperly processed. By using HeLa pLuc 705 cells, stably transfected with this plasmid, various vectors can be evaluated by measuring the luciferase activity in cells. This assay has been widely used in the last 3 years to assess the delivery efficacy of CPPs [11, 24, 26, 27] . Apart from different CPPs, different conjugation strategies and cargo-coupling positions to oligonucleotides have also been evaluated. In the study from Bendifallah et al. [28] , it was concluded that transportan was the most potent vector for delivery of asONs and that PNA-coupling positions significantly affect the activity. No simple correlation between linker type and antisense activity was observed [28] . Indeed, we have shown that transportan is superior to Tat and penetratin in conveying splice-correcting PNA and the peptide can also promote splicing in serum-containing medium in contrast with the other two peptides [11] .
One major breakthrough with the abovementioned assay, as it generates a positive readout, is that it allows thorough mechanistic studies on the uptake mechanism of CPPs. Several groups have recently shown that endosomolytic agents such as chloroquine improve peptide asON-mediated splicing severalfold, emphasizing that CPPs are internalized via endocytosis [11, [29] [30] [31] . Hence this assay provides a new platform for a means of screening new CPPs with enhanced ability to escape from endosomes. This is highly important since the major therapeutic limitation of CPPs appears to be endosomal entrapment. One good example of rational peptide design in that direction is the (R-Ahx-R) 4 (6-aminohexanoic spaced oligoarginine) peptide that allows efficient splice correction in the absence of endosomolytic agents [24] . Although promising, CPPs have not been used to date to target a biologically relevant pre-mRNA and it is therefore too early to draw any definite conclusions regarding its true therapeutic value.
Decoy delivery
By introducing a specific dsDNA (double-stranded DNA) decoy, mimicking a promoter sequence, into the cell, the activity of a specific transcription factor can be decreased [32] . But, as for many other therapeutics, bioavailability of dsDNA is very poor. By connecting TP10 to the consensus sequence corresponding to the NF-κB (nuclear factor κB) DNA-binding site, Fisher et al. [33] were able to block the effect of IL (interleukin)-1β-induced NF-κB activation and IL-6 gene expression [33] . The same strategy, together with co-incubation of CPP and decoy DNA, has been employed to reduce the activity of the transcription factor c-Myc, reducing proliferation of N2a cells. Interestingly, various endocytosis inhibitors had no effect on the uptake pattern, suggesting that uptake of these complexes is not mediated via endocytosis [34] .
Other cargoes
There are bioactive cargoes that are hard to categorize, such as DNA-binding TFOs (triplex-forming oligonucleotide molecules). By conjugating penetratin to TFOs, a 20-fold increase in mutation frequency has been achieved in vitro [35] . Most of the cargoes discussed in this article are oligonucleotides, or analogues thereof. But proteins are also greatly involved in gene regulation. For a better understanding concerning the role of RBPs (RNA-binding proteins) in the regulation of gene expression, methods to identify RNAprotein interactions are needed. By targeting specific regions of mRNA with an antisense PNA-CPP conjugate coupled to a photoactivatable amino acid, a range of mRNA-binding proteins has been isolated [36] .
